Core Viewpoint - Neuronetics, Inc. reported a mixed performance in its Q3 2025 earnings, with a slight miss on EPS estimates but significant year-over-year revenue growth Financial Performance - The company reported an EPS of -$0.13, missing the estimated EPS of -$0.12 by 18.18% [1][5] - Revenue for the quarter was $37.3 million, slightly below the estimated $37.8 million, representing a 2.21% miss [3][5] - Year-over-year, revenue increased significantly from $18.53 million in the same quarter last year [3] Comparison to Previous Periods - The current EPS of -$0.13 shows improvement from a loss of $0.29 per share in the same quarter last year [2] - In the previous quarter, the company reported a loss of $0.15 per share, missing the expected loss of $0.08, resulting in an 87.5% negative surprise [2] Revenue Breakdown - The Greenbrook clinic contributed $21.8 million to the revenue, reflecting a 25% increase from Q3 2024 [3] Valuation Metrics - Neuronetics has a price-to-earnings (P/E) ratio of -3.81, indicating negative earnings [4] - The price-to-sales ratio stands at 1.65, suggesting investors pay $1.65 for every dollar of sales [4] - The enterprise value to sales ratio is 2.28, reflecting the company's valuation relative to sales [4] - Despite negative earnings, the company maintains a strong liquidity position with a current ratio of 2.02 [4][5]